No retraction, correction or concern found when last checked on Oct 19, 2026.

Plasmodium vivax in the Era of the Shrinking P. falciparum Map

Ric N. Price, Robert J. Commons, Katherine E. Battle and 2 more

Trends in Parasitology · 2020 · Review · CC BY

doi:10.1016/j.pt.2020.03.009

Abstract

Plasmodium vivax is an important cause of malaria, associated with a significant public health burden. Whilst enhanced malaria-control activities have successfully reduced the incidence of Plasmodium falciparum malaria in many areas, there has been a consistent increase in the proportion of malaria due to P. vivax in regions where both parasites coexist. This article reviews the epidemiology and biology of P. vivax, how the parasite differs from P. falciparum, and the key features that render it more difficult to control and eliminate. Since transmission of the parasite is driven largely by relapses from dormant liver stages, its timely elimination will require widespread access to safe and effective radical cure.

References 77

1.
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study · 2019
No notice
2.
Global Epidemiology of Plasmodium vivax · 2016
No notice
3.
Mendis K, et al. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97-106.
Not in our library10.4269/ajtmh.2001.64.97
4.
World Malaria Report: 2013. 2013.
Not in our library
5.
Gunalan K, et al. Plasmodium vivax infections of Duffynegative erythrocytes: historically undetected or a recent adaptation? Trends Parasitol. 2018;34:420-429.
Not in our library10.1016/j.pt.2018.02.006
6.
Growing evidence of Plasmodium vivax across malaria-endemic Africa · 2019
Corrected
7.
Ding XC, et al. Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles. PLoS Negl Trop Dis. 2017;11:e0005516.
Not in our library10.1371/journal.pntd.0005516
8.
Michon P, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007;76:997-1008.
Not in our library
9.
Douglas NM, et al. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis. 2013;208:801-812.
Not in our library10.1093/infdis/jit261
10.
White NJ, et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J. 2014;13:483.
Not in our library10.1186/1475-2875-13-483
11.
Collins WE, et al. Experimental infection of Anopheles farauti with different species of Plasmodium. J Parasitol. 2002;88:295-298.
Not in our library10.1645/0022-3395(2002)088[0295:eioafw]2.0.co;2
12.
Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
Not in our library10.1128/cmr.00051-10
13.
Sattabongkot J, et al. Plasmodium vivax transmission: chances for control? Trends Parasitol. 2004;20:192-198.
Not in our library10.1016/j.pt.2004.02.001
14.
Bockarie MJ, Dagoro H. Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J. 2006;5:15.
Not in our library10.1186/1475-2875-5-15
15.
Determinants of relapse periodicity in Plasmodium vivax malaria · 2011
No notice
16.
Geographical variation in Plasmodium vivax relapse · 2014
No notice
17.
Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis. 2013;13:900-906.
Not in our library10.1016/s1473-3099(13)70095-1
18.
Commons RJ, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:91-101.
Not in our library10.1016/s1473-3099(18)30596-6
19.
Hossain MS, et al. The risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: an individual patient data meta-analysis. 2019.
Not in our library
20.
The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos · 2019
Not checked
21.
Douglas NM, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612-620.
Not in our library10.1093/cid/ciq249
22.
Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36-57.
Not in our library10.1128/cmr.00074-12
23.
Anstey NM, et al. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012;80:151-201.
Not in our library10.1016/b978-0-12-397900-1.00003-7
24.
Baird JK. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev. 2019;32:e00011-e00019.
Not in our library10.1128/cmr.00011-19
25.
Patriani D, et al. Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infect Dis. 2019;19:922.
Not in our library10.1186/s12879-019-4497-y
26.
Douglas NM, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med. 2014;12:217.
Not in our library10.1186/s12916-014-0217-z
27.
Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study · 2013
No notice
28.
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study · 2012
No notice
29.
Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia · 2008
No notice
30.
Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea · 2008
No notice
31.
Dini S, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Med. 2020;18:28.
Not in our library10.1186/s12916-020-1497-0
32.
World Malaria Report 2019. 2019.
Not in our library
33.
Malaria in Brazil: an overview · 2010
No notice
34.
Rodriguez JC, et al. Epidemiology and control of malaria in Colombia. Mem Inst Oswaldo Cruz. 2011;106:114-122.
Not in our library10.1590/s0074-02762011000900015
35.
Kenangalem E, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Med. 2019;16:e1002815.
Not in our library10.1371/journal.pmed.1002815
36.
Ome-Kaius M, et al. Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children. BMC Med. 2019;17:220.
Not in our library10.1186/s12916-019-1456-9
37.
Chu CS, et al. Declining burden of Plasmodium vivax in a population in Northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription for radical cure. Am J Trop Med Hyg. 2019;102:147-150.
Not in our library10.4269/ajtmh.19-0496
38.
Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model · 2015
No notice
39.
Adekunle AI, et al. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis. 2015;9:e0003595.
Not in our library10.1371/journal.pntd.0003595
40.
Douglas NM, et al. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol. 2012;80:271-300.
Not in our library10.1016/b978-0-12-397900-1.00005-0
41.
Premaratne R, et al. Technical and operational underpinnings of malaria elimination from Sri Lanka. Malar J. 2019;18:256.
Not in our library10.1186/s12936-019-2886-8
42.
Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015–2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species · 2019
No notice
43.
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis · 2014
No notice
44.
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine–pyrimethamine in southern Papua, Indonesia · 2007
No notice
45.
Karunajeewa HA, et al. A trial of combination anti-malarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545-2557.
Not in our library10.1056/nejmoa0804915
46.
Grigg MJ, et al. Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial. Clin Infect Dis. 2016;62:1403-1411.
Not in our library10.1093/cid/ciw121
47.
Price RN, et al. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol. 2012;28:522-529.
Not in our library10.1016/j.pt.2012.08.005
48.
Popovici J, et al. Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for Plasmodium vivax malaria. J Infect Dis. 2019;219:315-322.
Not in our library10.1093/infdis/jiy484
49.
de Sena LWP, et al. Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin. Malar J. 2019;18:439.
Not in our library10.1186/s12936-019-3072-8
50.
Commons RJ, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Anti-malarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18:1025-1034.
Not in our library10.1016/s1473-3099(18)30348-7
51.
Douglas NM, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010;10:405-416.
Not in our library10.1016/s1473-3099(10)70079-7
52.
Commons RJ, et al. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Med. 2019;16:e1002928.
Not in our library10.1371/journal.pmed.1002928
53.
Gilder ME, et al. Primaquine pharmacokinetics in lactating women and breastfed infant exposures. Clin Infect Dis. 2018;67:1000-1007.
Not in our library10.1093/cid/ciy235
54.
von Seidlein L, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112.
Not in our library10.1186/1475-2875-12-112
55.
Guidelines for the Treatment of Malaria. 2015.
Not in our library
56.
Thriemer K, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.
Not in our library10.1186/s12936-018-2380-8
57.
Douglas NM, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med. 2017;14:e1002379.
Not in our library10.1371/journal.pmed.1002379
58.
Primaquine radical cure of Plasmodium vivax: a critical review of the literature · 2012
No notice
59.
Rajgor D, et al. Antirelapse efficacy of various primaquine regimens for Plasmodium vivax. Malar Res Treat. 2014;2014.
Not in our library10.1155/2014/347018
60.
Saravu K, et al. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malar J. 2018;17:321.
Not in our library10.1186/s12936-018-2472-5
61.
Milligan R, et al. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2019;7.
Not in our library10.1002/14651858.cd012656.pub2
62.
Chu CS, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2019;68:1311-1319.
Not in our library10.1093/cid/ciy735
63.
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial · 2019
No notice
64.
Ariffin NM, et al. Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. Parasitol Res. 2019;118:1011-1018.
Not in our library10.1007/s00436-019-06210-3
65.
Baird JK, et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Netw Open. 2018;1:e181449.
Not in our library10.1001/jamanetworkopen.2018.1449
66.
Zhou Y, et al. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688-700.
Not in our library10.1002/cpt.690
67.
Tan KR, Hwang J. Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax. J Travel Med. 2018;25:tay071.
Not in our library10.1093/jtm/tay071
68.
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria · 2019
No notice
69.
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria · 2019
No notice
70.
Haston JC, et al. Guidance for using tafenoquine for prevention and antirelapse therapy for malaria – United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:1062-1068.
Not in our library10.15585/mmwr.mm6846a4
71.
Commons RJ, et al. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212:e151.
Not in our library10.5694/mja2.50474
72.
Ley B, et al. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLoS Med. 2019;16:e1002992.
Not in our library10.1371/journal.pmed.1002992
73.
Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. · 2018
Not checked
74.
Ashley EA, et al. Plasmodium vivax relapse rates following Plasmodium falciparum malaria reflect previous transmission intensity. J Infect Dis. 2019;220:100-104.
Not in our library10.1093/infdis/jiz052
75.
Mayxay M, et al. Mixed-species malaria infections in humans. Trends Parasitol. 2004;20:233-240.
Not in our library10.1016/j.pt.2004.03.006
76.
Thriemer K, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16:141.
Not in our library10.1186/s12936-017-1784-1
77.
Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal modelling study · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.